Egle Therapeutics, a Paris, France-based biotechnology company that focuses on developing First-In-Class immunotherapies targeting immune suppressor regulatory T-cells (Tregs) for oncology and autoimmune diseases, completed a €40M ($46.4M) Series A financing.
The round was co-led by LSP and Bpifrance through their InnoBio 2 fund, with participation from Fund+, Bioqube Ventures and Takeda Ventures.
The new capital will be used primarily to advance 2 leads assets into the clinic and further strengthen its internal drug pipeline.
Established in early 2020, as a spin-out of Institut Curie by Luc Boblet, serial biotech entrepreneur and Dr Eliane Piaggio, PhD, renowned immunologist in the Treg / IL-2 field (INSERM Research Director, Head of the Translational Immunotherapy Team – TransImm – at Institut Curie), Egle Therapeutics develops First-In-Class immunotherapies targeting immune suppressor regulatory T cells (Tregs) for oncology and autoimmune diseases.
Its scientific foundation leverages computational-based, IL-2 modified variants and newly tumor-associated Treg targets to build a pipeline of First-In-Class immunocytokines against Tregs.
The investor syndicate will join the Egle Therapeutics Board which will consist of Felice Verduyn-van Weegen (LSP), Vincent Brichard (LSP), Jean-Francois Morin (Bpifrance – InnoBio 2) and Sacha Mann (Takeda Ventures). Philippe Monteyne (Fund+), Jacques Mizrahi (Bioqube Ventures) and Elisa El Nouchi (Bpifrance InnoBio 2) will join as observers.
FinSMEs
22/10/2021